The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Hepatocellular Carcinoma Confirmation, Treatment, and Survival in Surveillance, Epidemiology, and End Results Registries, 1992-2008
Open accessAbstract
Approaches to the diagnosis and management of hepatocellular carcinoma (HCC) are improving survival. In the Surveillance, Epidemiology, and End Results-13 registries, HCC stage, histological confirmation, and first-course surgery were examined. Among 21,390 HCC cases diagnosed with follow-up of vital status during 1998-2008, there were 4,727 (22%) with reported first-course invasive liver surgery, local tumor destruction, or both. The proportion with reported liver surgery or ablation was 39% among localized stage cases and only 4% among distant/unstaged cases. Though 70% of cases had histologically confirmed diagnoses, the proportion with confirmed diagnoses was higher among cases with reported invasive surgery (99%), compared to cases receiving ablation (81%) or no reported therapy (65%). Incidence rates of histologically unconfirmed HCC increased faster than those of confirmed HCC from 1992 to 2008 (8% versus 3% per year). Two encouraging findings were that incidence rates of localized-stage HCC increased faster than rates of regional- and distant-stage HCC combined (8% versus 4% per year), and that incidence rates of reported first-course surgery or tumor destruction increased faster than incidence rates of HCC without such therapy (11% versus 7%). Between 1975-1977 and 1998-2007, 5-year cause-specific HCC survival increased from just 3% to 18%. Survival was 84% among transplant recipients, 53% among cases receiving radiofrequency ablation at early stage, 47% among cases undergoing resection, and 35% among cases receiving local tumor destruction. Asian or Pacific Islander cases had significantly better 5-year survival (23%) than white (18%), Hispanic (15%), or black cases (12%). Conclusion: HCC survival is improving, because more cases are diagnosed and treated at early stages. Additional progress may be possible with continued use of clinical surveillance to follow individuals at risk for HCC, enabling early intervention. (Hepatology 2012;)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Permutation tests for joinpoint regression with applications to cancer rates
Kim, H.-J., Fay, M. P., Feuer, E. J., & Midthune, D. N. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z · Cited by 6,318
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Self-citationDiagnosis and Treatment of Hepatocellular Carcinoma
El-Serag, H. B., Marrero, J. A., Rudolph, L., & Reddy, K. R. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.090 · Cited by 1,137
Kim, H. (2001) · Statistics in Medicine · doi:10.1002/sim.811 · Cited by 873
Hepatocellular Carcinoma: Current Management and Perspectives for the Future
Rahbari, N. N., Mehrabi, A., Mollberg, N. M., Müller, S. A., Koch, M., Büchler, M. W., & Weitz, J. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820d944f · Cited by 453
Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data
Howlader, N., Ries, L. A. G., Mariotto, A. B., Reichman, M. E., Ruhl, J., & Cronin, K. A. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq366 · Cited by 452
Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis
Sherman, M. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247128 · Cited by 396
El-Serag, H. B., Mason, A. C., & Key, C. (2001) · Hepatology · doi:10.1053/jhep.2001.21041 · Cited by 353
Artinyan, A., Mailey, B., Sanchez‐Luege, N., Khalili, J., Sun, C., Bhatia, S., Wagman, L. D., Nissen, N., Colquhoun, S. D., & Kim, J. (2010) · Cancer · doi:10.1002/cncr.24817 · Cited by 250
Mathur, A. K., Osborne, N. H., Lynch, R., Ghaferi, A. A., Dimick, J. B., & Sonnenday, C. J. (2010) · Archives of Surgery · doi:10.1001/archsurg.2010.272 · Cited by 146
Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance
Yang, J. D., Harmsen, W. S., Slettedahl, S. W., Chaiteerakij, R., Enders, F., Therneau, T. M., Orsini, L. S., Kim, W. R., & Roberts, L. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.027 · Cited by 132
National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003.
Ahmed, F., Perz, J. F., Kwong, S. L., Jamison, P. M., Friedman, C., & Bell, B. P. (2008) · PubMed Central · Cited by 79
Chronic Hepatitis B and Hepatocellular Carcinoma
McClune, A. C., & Tong, M. J. (2010) · Clinics in Liver Disease · doi:10.1016/j.cld.2010.05.009 · Cited by 79
Wong, R. J., & Corley, D. A. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0661-8 · Cited by 45
Loco-Regional Treatment of Hepatocellular Carcinoma in the Era of Molecular Targeted Therapies
Lencioni, R. A. (2010) · Oncology · doi:10.1159/000315238 · Cited by 42
Cited by
Emerging trends in hepatocellular carcinoma incidence and mortality
Njei, B., Rotman, Y., Ditah, I., & Lim, J. K. (2015) · Hepatology · doi:10.1002/hep.27388 · Cited by 539
Liu, C.-Y., Chen, K.-F., & Chen, P.-J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021535 · Cited by 391
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 363
Nath, A., Li, I., Roberts, L. R., & Chan, C. (2015) · Scientific Reports · doi:10.1038/srep14752 · Cited by 338
Liver Resection and Surgical Strategies for Management of Primary Liver Cancer
Orcutt, S. T., & Anaya, D. A. (2018) · Cancer Control · doi:10.1177/1073274817744621 · Cited by 337
Metadata
- Authors
- Altekruse, S. F., McGlynn, K. A., Dickie, L. A., & Kleiner, D. E.
- Venue
- Hepatology
- Published
- 2012-02
- Volume
- 55
- Issue
- 2
- Pages
- 476-482
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2051300948
- Cited by
- 262
- References
- 16
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.